Portal to Wellness Tirzepatide 15mg lyophilised research vial, front label

15% OFF

Portal to Wellness Tirzepatide 15mg vial, alternate angle showing crimp seal and stopper

Tirzepatide – 15mg/vial (Research Use Only)

Name: Tirzepatide – 15mg/vial (Research Use Only)
Brand: Portal to Wellness
SKU: TIRZ15
Price: 39 USD
Availability: InStock

— or subscribe to save 10% You save $6.88

Dual GIP/GLP-1 receptor agonist peptide, widely studied in metabolic and body-composition research. Current testing status is stated in full on our Lab Testing & Verification page.

Availability: In stock

Volume pricing
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.

Research Disclaimer: All products currently listed on this site are for research purposes only.

Dual GIP and GLP-1 receptor activation — a distinct mechanism from single-incretin compounds
SURMOUNT-1 (2022) is the principal published Phase 3 trial in the tirzepatide literature
GIP receptor activity is studied for its effects on adipose tissue lipid metabolism
Insulin sensitivity is a reported endpoint across the published trial programme
Extended half-life relative to the native incretin hormones

Ships in 1-2 Business Days Discreet, temperature-controlled packaging

Research Support Included Chat & email — our team knows the research

One-time purchase
Subscribe to save 10%

one time
Original price was: $45.88.Current price is: $35.10. / month — save 10%
Original price was: $45.88.Current price is: $35.10. every 3 weeks — save 10%

How the subscription works

Pick how often you want it. We email a reminder 7 days before each delivery is due, then the invoice itself.
Nothing is charged automatically. You pay each invoice the same way you pay any order — Zelle or crypto.
Every renewal is 10% off, and volume pricing still applies on top of that.
Cancel or pause from your account at any time. No minimum and no notice period.
Orders over $150 ship free, renewals included.

Research Grade ≥98% purity standard

Fast Fulfillment Ships in 1–2 days

Most reordered metabolic research product

Why Researchers Explore Tirzepatide – 15mg/vial (Research Use Only)

Overview

Backed by the ResearchRead: SURMOUNT-MMO Trial Explained →

Tirzepatide is a synthetic dual-agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual-receptor mechanism provides a pharmacological tool for studying complementary incretin signaling pathways simultaneously, and it has been extensively examined in published preclinical and clinical pharmacology literature focused on metabolic, cardiovascular, and hepatic biology.

What It Is

Tirzepatide is a 39-amino acid synthetic peptide designed as a dual agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It is based on the native GIP sequence with modifications enabling GLP-1 receptor co-activation and a C20 fatty diacid chain at lysine-26 for extended half-life via albumin binding. Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈. Molecular weight: approximately 4,813.45 Da. CAS number: 2023788-19-2.

Research Spotlight

The research profile of tirzepatide is defined by its dual-receptor mechanism, which activates both the GIP and GLP-1 pathways — systems with distinct but overlapping roles in postprandial glucose regulation, insulin secretion, glucagon suppression, and energy homeostasis. Published preclinical research has investigated tirzepatide’s differential effects on adipose tissue (GIP receptor-mediated) versus appetite and gastric motility (GLP-1 receptor-mediated), providing mechanistic data for comparative metabolic studies. Cardiovascular research has examined lipid profiles, myocardial inflammation markers, and vascular remodeling parameters in animal models. Comparative pharmacology studies have evaluated tirzepatide against semaglutide and other GLP-1 agonists to quantify receptor binding affinity and tissue-specific signaling differences. Additional published research has explored renal and hepatic biomarker responses in NASH and kidney function models, as well as skeletal muscle protein synthesis pathways in relevant animal preparations.

Key Research Applications

Dual GIP and GLP-1 receptor co-activation and downstream signaling studies
Comparative receptor pharmacology vs. GLP-1 mono-agonist compounds
Pancreatic beta-cell insulin secretion and glucose-dependent insulinotropic modeling
Adipose tissue biology, lipolysis, and body composition research
Appetite, satiety signaling, and central GLP-1 pathway investigations
Cardiovascular risk marker modulation and cardiac inflammation research
NASH, hepatic steatosis, and renal function marker studies
Skeletal muscle protein synthesis and lean mass preservation modeling
Long-acting fatty acid-conjugated peptide pharmacokinetics
Incretin receptor selectivity and synergy research

For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.

Not sure which compounds fit your research? Browse the Research Hub →

Frequently Asked Questions — Tirzepatide

What makes Tirzepatide a dual agonist and why does it matter?

Tirzepatide binds both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. In the published literature, GLP-1 receptor agonism is associated with delayed gastric emptying and altered satiety signalling, while GIP receptor agonism is associated with glucose-dependent insulin secretion and a possible role in adipose tissue metabolism. Studies of the dual mechanism report metabolic endpoints distinct from those of single-receptor GLP-1 agonists. These findings come from clinical trials of pharmaceutical-grade tirzepatide conducted under medical supervision and are provided as background on the molecule.

How does Tirzepatide differ from Semaglutide mechanistically?

Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide binds both the GLP-1 and the GIP receptor, so the two compounds engage different receptor sets. The published trial programmes for each measured body-weight and HbA1c endpoints, and comparative analyses exist in that literature. Portal to Wellness does not reproduce figures from those trials on product pages: they describe pharmaceutical-grade material given to people under medical supervision, which is not what is sold here.

What has published research examined for Tirzepatide?

The SURPASS and SURMOUNT clinical trial programs evaluated Tirzepatide across metabolic and body-composition endpoints, and comparative studies have measured its receptor binding and tissue-specific signaling against other incretin compounds. PTW Tirzepatide is supplied for laboratory research purposes only and is not intended for human use.

What purity standard applies to this tirzepatide?

The supplier specification is ≥98% purity. Portal to Wellness supplies it for laboratory research use only.

What is the molecular structure of Tirzepatide compared to native GIP?

Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, modified to incorporate GLP-1 receptor affinity. A C20 fatty diacid chain is attached via a linker to enable albumin binding and extend the half-life to approximately 5 days.